Quality and Innovation are Not Incompatible
Reports from the 2017 PDA/FDA Joint Regulatory Conference
![Peter Marks Peter Marks](/images/default-source/default-album/pda-letter/new-portal/articles/january-2018/peter-marks.jpg?sfvrsn=1ea08e8e_0)
CBER Director Peter W. Marks discusses his perspective on innovation
Quality is essential no matter how revolutionary the drug product. That concept permeated the 2017 PDA/FDA Joint Regulatory Conference: “Ensuring Product Quality in an Era of Innovative Therapies,” Sept. 11–13, in Washington, D.C.
Three sessions in particular emphasized the spirit behind the theme of the meeting.